Orphan Drugs Market 2015-2019

2015-11-11
Price :
Published : Nov-2015
No. of Pages : 108

An orphan drug is used to treat rare diseases or disorders. According to WHO, orphan or rare diseases are the pathological conditions that affect 0.65-1 out of 10,000 population worldwide. There are around 6,000 orphan diseases, of which 80% are genetic. Orphan drugs are developed by the pharmaceutical industry to serve the public health need. These are designated as “Orphan Designations” by the regulatory agencies to accelerate the approval process.

The analysts forecast global orphan drugs market to grow at a CAGR of 10.05% over the period 2014-2019.

Covered in this report

The report covers the current scenario and the growth prospects of the global orphan drugs market for the period of 2015-2019. To calculate the market size, the report considers revenue generated from the sales orphan drugs.

The report, Global Orphan Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and Europe; it also covers the landscape of the global orphan drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • Europe

Key vendors

  • Bristol-Mayer Squibb
  • Celgene
  • F. Hoffmann La Roche
  • Novartis
  • Pfizer

Other prominent vendors

  • AbbVie
  • Actelion Pharmaceuticals
  • Alexion Pharmaceuticals
  • Alnylam Pharmaceuticals
  • Amgen
  • AstraZeneca
  • Baxter International
  • Biogen Idec
  • Celldex Therapeutics
  • Eisai
  • Eli Lilly
  • GlaxoSmithKline
  • Intercept Pharmaceuticals
  • Johnson & Johnson
  • Merck
  • NewLink Genetics
  • Northwest Biotherapeutics
  • Novo Nordisk
  • Onyx Pharmaceuticals
  • Sanofi
  • Shire
  • Synageva BioPharma
  • Takeda
  • Vertex Pharmaceuticals
  • XOMA

Market driver

  • Shorter development timelines
  • For a full, detailed list, view our report

Market challenge

  • High cost of drug development
  • For a full, detailed list, view our report

Market trend

  • Increased focus on biological drugs
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
Filed in: Pharmaceutical
Publisher : Infiniti Research Limited
More Reports
Title Price Buy Now

Global Foot Insoles Market 2017-2021

Due to its structural nature, the human foot is intended to walk on natural grounds and without the use of high heels. The unusual inclined position of the foot due to heels and often flat floor will result in damage to the foot and therefore, in the podalgia. Most humans are born with healthy feet. Damage to the feet predominantly develops with time. The causes are disposition, overweight, hard grounds, wrong footwear, sport injuries, rheumatic changes, circulatory disorders, and neuropathies. The analysts forecast global foot insoles market to grow at a CAGR of 6.64% during the period 2017-2021. Covered in this report The report covers the present scenario and the growth prospects of the global foot insoles market for 2017-2021. To calculate the market size, the report considers......
$3500

Global Protein Therapeutics Market 2017-2021

Therapeutic proteins are used to effectively treat a wide array of diseases such as protein deficiency diseases; chronic diseases such as cancer, rheumatoid arthritis (RA), ankylosing spondylitis, diabetes; infections such as human immunodeficiency virus (HIV), hepatitis A, hepatitis B, and hepatitis C; and other medical conditions such as genetic disorders, anemia cases related to kidney dialysis, and cancer-related anemia. Therapeutic proteins mostly consist of recombinant forms of naturally occurring proteins. The analysts forecast global protein therapeutics market to grow at a CAGR of 7.86% during the period 2017-2021. Covered in this report The report covers the present scenario and the growth prospects of the global protein therapeutics market for 2017-2021. To calculate th......
$3500

Global Chemotherapy-induced Nausea and Vomiting Drugs Market 2017-2021

The launch of extended half-life drugs in the market is expected to substantially improve the adoption rates, owing to their ability to act for prolonged periods of time. For instance, Heron Therapeutics' SUSTOL and Tesaro's VARUBI offer protection against CINV for five days and seven days, respectively. Additionally, the emergence of oral therapies is expected to enhance the patient compliance, resulting in market growth. The analysts forecast global CINV drugs market to grow at a CAGR of 5.41% during the period 2017-2021. Covered in this report The report covers the present scenario and the growth prospects of the global CINV drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of CINV drugs. The market is divided......
$3500

Global Infantile Spasms Therapeutics Market 2017-2021

An infantile spasm is a particular type of seizure found in an epilepsy syndrome of infancy and childhood. It is also known as a West syndrome. The onset of infantile spasm is usually found in the first year of life between four months and eight months of age. The condition constitutes 2% of childhood epilepsies and 25% of epilepsies with onset in the first year of life. There are around 2,000-4,000 new cases observed in the US each year. The overall long-term prognosis for infantile spasms patients is poor. It has been found that 50%-70% of infantile spasms patients develop other seizure types and 18%-50% will develop Lennox-Gastaut syndrome (LGS) or other forms of symptomatic generalized epilepsy. The analysts forecast global infantile spasms therapuetics market to grow at a CAGR of 1......
$3500

Global Cancer Monoclonal Antibodies Market 2017-2021

The mAbs, which are produced by genetic engineering, target antigens in cells, tissues, and organs. They are used in clinical applications to treat diseases with excellent efficacy and minimal side effects. Their MOA, absence of generic pathway, and therapeutic applications distinguish them from other targeted therapeutics. The analysts forecast the global cancer monoclonal antibodies market to grow at a CAGR of 10.86% during the period 2017-2021. Covered in this report This report covers the present scenario and the growth prospects of the global cancer monoclonal antibodies market for 2017-2021. To calculate the market size, This report considers the revenue generated from the sales of branded cancer mAbs and biosimilars used to treat cancer. It also considers the revenues to be......
$3500

Global Multiple Myeloma Drugs Market 2017-2021

Multiple myeloma is an abnormal growth and accumulation of plasma cells in the bone marrow leading to malignancy. This can be caused by the overproduction of monoclonal immunoglobulins such as IgG, IgA, IgD, or IgE; or Bence-Jones protein. Under normal conditions, stem cells develop into B lymphocytes, mature in the lymph nodes, and are transported throughout the body. On the entry of foreign substances into the body, these B-cells develop into plasma cells and produce immunoglobulins against the disease. However, in multiple myeloma, the B-cells are damaged and give rise to many malignant plasma cells that produce excessive immunoglobulins of a single type, which the body does not require. The analysts forecast the global multiple myeloma drugs market to grow at a CAGR of 9.19% during ......
$3500

Global Smart Healthcare Market 2016-2020

Smart healthcare is the integration of different healthcare delivery mechanisms. It makes use of electronic patient records and streamlining processes, which leads to improved quality of life by reducing the risks to health (by remote monitoring and checks) and improving the general well-being of people. Smart healthcare provides more patient-centric services that improves access to healthcare and are customized to individual patients' needs. The analysts forecast global smart healthcare market to grow at a CAGR of 24.55% during the period 2016-2020. Covered in this report This report covers the present scenario and the growth prospects of the global smart healthcare market for 2016-2020. To calculate the market size, the report considers the revenue generated from solutions EHR, ......
$2500

Nurse Call System Market in the US 2016-2020

The NCS helps a caregiver and a patient to effectively communicate with each other and enhance patient care. In the US, individuals undergoing treatment in specialized healthcare facilities such as in SNFs, ALFs, and ACFs need constant attention and care. Hence, to provide 24/7 care to them, there is a need for a dedicated line of communication between patients and caregivers; NCS are used for this purpose. The analysts forecast nurse call system market in the US to grow at a CAGR of 14.18% during the period 2016-2020. Covered in this report This report covers the present scenario and the growth prospects of the nurse call system market in the US for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of NCS, including nurse call comp......
$2500

Global Pompe Disease Treatment Market 2016-2020

Lysosomal storage diseases (LSDs) are a group of progressive, autosomal recessive, and hereditary disorders characterized by the accumulation of specific substrates and variable age of onset and clinical symptoms. Pompe disease, a type of LSD, is caused by mutations in the GAA gene. These mutations inhibit the mechanism of action (MOA) of GAA; it is an enzyme responsible for catabolizing glycogen, resulting in accumulation of glycogen to toxic levels in the lysosomes of the cells. The buildup of glycogen in certain tissues and organs, especially in the muscles, hinders the normal functions of the organs. It can be further divided as adult-onset and infantile-onset Pompe diseases. As the disease is an autosomal recessive hereditary disorder, both parents are carriers and pass one copy of th......
$2500

Global Human Respiratory Syncytial Virus Drugs Market 2016-2020

Respiratory syncytial virus (RSV) is a virus that leads to infections in the lungs and the respiratory tract. It commonly affects most children in the ages 2 or below. RSV can also infect adults. In adults and the older population, the symptoms of RSV are mild and similar to that of common cold. Infection with RSV can be severe in certain cases, particularly in premature infants and babies with underlying health conditions. RSV can also become serious in the older population or adults with heart and lung diseases, or any individual with a very weak immune system. The analysts forecast global human respiratory syncytial virus drugs market to grow at a CAGR of 4.27% during the period 2016-2020. Covered in this report This report covers the present scenario and the growth prospects o......
$2500